特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 专业诊断部门 的收入为11 . 4 8亿美元，与2 0 2 4年第一季度相比略涨0 . 3 9亿美元。 | Business Segment Information | | Three months ended | | | | --- | --- | --- | --- | --- | | | March 29, | % of | March 30, | % of | | (Dollars in millions) | 2025 | Revenues | 2024 | Revenues | | Revenues | | | | | | Life Sciences Solutions | 2,341 | 22.6% S | 2,285 | 22.1% | | Analytical Instruments | 1,718 | 16.6% | 1,687 | 16.3% | | Specialty Diagnostics | 1,148 | 11.1% | 1,109 | 10.7% | | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Views - The company has achieved strong positive results in head-to-head trials of its drug, Iwosimab, against Tremelimumab for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC), with significant clinical benefits expected from the upcoming MRCT data readout in mid-2025 [1][2] - The company is well-positioned in the NSCLC market with comprehensive strategies and leading data, anticipating a valuation uplift from global clinical data verification [2][3] - The company is expected to experience significant revenue growth and profitability improvements due to the inclusion of its drugs in medical insurance and the upcoming clinical data readouts [3][4] Financial Summary - Revenue projections for the company are estimated at 3.39 billion, 5.48 billion, and 6.77 billion yuan for 2025, 2026, and 2027 respectively, with net profits expected to be 71 million, 936 million, and 1.605 billion yuan for the same years [4][6] - The earnings per share (EPS) is projected to improve from -0.57 yuan in 2024 to 1.79 yuan in 2027, indicating a strong recovery and growth trajectory [6][4]

一次性使用细胞生物反应器和发酵罐是专用的生物处理设备，设计用于在一次性使用配置中培养细胞或发酵微生物。就一次性使用 细胞生物反应器而言，它们为哺乳动物、微生物或植物细胞的生长提供了受控环境，使单克隆抗体、重组蛋白和疫苗等生物制药的 生产成为可能。同样，一次性发酵罐也用于细菌、酵母或其他微生物的生长，以生产包括酶、生物燃料和有机酸在内的多种产品。 这些一次性使用系统通常由塑料薄膜或硬质聚合物等材料制成的一次性生物反应器或发酵容器，以及用于控制温度、 pH 值、溶解 氧和搅拌等参数的集成传感器和端口组成。它们无需在批次之间进行耗时且成本高昂的清洗和灭菌程序，从而降低了交叉污染的风 险，加快了整个生产流程。因此，它们非常适用于对产品快速转换、灵活性和减少停机时间要求极高的应用领域，如研发、小规模 生产和个性化药品生产等。 一次性使用细胞生物反应器和发酵器全球市场总体规模 据 QYResearch 调研团队最新报告"全球一次性使用细胞生物反应器和发酵器市场报告 2025-2031 "显示，预计 2031 年全球一次性使 用细胞生物反应器和发酵器市场规模将达到 13.2 亿美元，未来几年年复合增长率 CAGR 为 8. ...